Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.

The TARDIS targeted digital sequencing assay was used at a single time point to compare ctDNA in people with metastatic renal cell carcinoma who had a complete versus partial response to immune checkpoint inhibition.

JCO Precision OncologyPubMed 37027813DOI 10.1200/PO.22.00543